Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether PRO044 is safe and effective to use as medication
for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA
for the dystrophin protein.